Dr Davids
Al-Sawaf O et al. Venetoclax-obinutuzumab for previously untreated chronic lymphocytic leukemia: 6-year results of the randomized phase 3 CLL14 study. Blood 2024;144(18):1924-35. Abstract
Brown JR et al. Fixed-duration acalabrutinib combinations in untreated chronic lymphocytic leukemia. N Engl J Med 2025;392(8):748-62. Abstract
Burger JA et al. Final analysis of the RESONATE-2 study: Up to 10 years of follow-up of first-line ibrutinib treatment for CLL/SLL. Blood 2025;146(18):2168-76. Abstract
Davids MS et al. Phase II study of acalabrutinib, venetoclax, and obinutuzumab in a treatment-naïve chronic lymphocytic leukemia population enriched for high-risk disease. J Clin Oncol 2025;43(7):788-99. Abstract
Davids MS et al. Acalabrutinib-based regimens in frontline or relapsed/refractory higher-risk CLL: Pooled analysis of 5 clinical trials. Blood Adv 2024;8(13):3345-59. Abstract
Davids MS et al. Real-world characteristics, treatment patterns, and outcomes of patients with 2 or more LOTs for CLL/SLL in the United States. Blood Neoplasia 2024;2(1):100047. Abstract
Fürstenau M et al. The triple combination of venetoclax-ibrutinib-obinutuzumab prolongs progression-free survival compared to venetoclax-CD20-antibody combinations and chemoimmunotherapy in treatment-naive chronic lymphocytic leukemia: Final analysis from the phase 3 GAIA/CLL13 trial. EHA 2025;Abstract S191.
Jurczak W et al. Pirtobrutinib vs bendamustine plus rituximab (BR) in patients with CLL/SLL: First results from a randomized phase III study examining a non-covalent BTG inhibitor in untreated patients. ASH 2025;Abstract LBA-3.
Liu J et al. Sonrotoclax overcomes BCL2 G101V mutation-induced venetoclax resistance in preclinical models of hematologic malignancy. Blood 2024;143(18):1825-36. Abstract
Shadman M et al. Zanubrutinib versus bendamustine and rituximab in patients with treatment-naïve chronic lymphocytic leukemia/small lymphocytic lymphoma: Median 5-year follow-up of SEQUOIA. J Clin Oncol 2025;43(7):780-7. Abstract
Shadman M et al. CELESTIAL-TNCLL: An ongoing, open-label, multiregional, phase 3 study of sonrotoclax (BGB-11417) + zanubrutinib vs venetoclax + obinutuzumab for treatment-naïve (TN) CLL. ASCO 2024;Abstract TPS7087.
Sharman JP et al. Acalabrutinib-obinutuzumab improves survival vs chemoimmunotherapy in treatment-naive CLL in the 6-year follow-up of ELEVATE-TN. Blood 2025;146(11):1276-85. Abstract
Soumerai JD et al. Sonrotoclax and zanubrutinib as frontline treatment for CLL demonstrates high MRD clearance rates with good tolerability: Data from an ongoing phase 1/1b study BGB-11417-101. Blood 2024;144(1_Suppl):1012. Abstract
Tam CS et al. Zanubrutinib in the treatment of patients with del(17p) and/or TP53 CLL/SLL: Analysis across clinical studies. Blood Adv 2025;[Online ahead of print]. Abstract
Woyach J et al. Pirtobrutinib vs ibrutinib in treatment-naïve and relapsed/refractory CLL/SLL: Results from the first randomized study III study comparing a non-covalent and covalent BTK inhibitor. ASH 2025;Abstract 87.
Prof Tam
Brown JR et al. Fixed-duration acalabrutinib combinations in untreated chronic lymphocytic leukemia. N Engl J Med 2025;392(8):748-62. Abstract
Munir T et al. Practical management of cardiovascular adverse events with BTKi treatment in patients with chronic lymphocytic leukemia: A consensus report by hematologists and cardiologists. Acta Haematol 2025;[Online ahead of print]. Abstract
Shadman M et al. Zanubrutinib and venetoclax for patients with treatment-naïve chronic lymphocytic leukemia/small lymphocytic lymphoma with and without del(17p)/ TP53 mutation: SEQUOIA arm D results. J Clin Oncol 2025;43(21):2409-17. Abstract
Timofeeva N et al. Ibrutinib and venetoclax in combination for chronic lymphocytic leukemia: Synergy in practice. Blood Neoplasia 2024;1(3):100034. Abstract
Dr Woyach
Davids M et al. Preliminary results of the ongoing multicenter, phase 2 study of retreatment with venetoclax plus obinutuzumab (REVENG) in patients with recurrent chronic lymphocytic leukemia (CLL). EHA 2025;Abstract PF575.
Jain N et al. Absence of BTK, BCL2, and PLCG2 mutations in chronic lymphocytic leukemia relapsing after first-line treatment with fixed-duration ibrutinib plus venetoclax. Clin Cancer Res 2024;30(3):498-505. Abstract
Sharman JP et al. Phase III trial of pirtobrutinib versus idelalisib/rituximab or bendamustine/rituximab in covalent bruton tyrosine kinase inhibitor-pretreated chronic lymphocytic leukemia/small lymphocytic lymphoma (BRUIN CLL-321). J Clin Oncol 2025;43(22):2538-49. Abstract
Sharman JP et al. BRUIN CLL-321: Randomized phase III trial of pirtobrutinib versus idelalisib plus rituximab (idelar) or bendamustine plus rituximab (br) in BTK inhibitor pretreated chronic lymphocytic leukemia/small lymphocytic lymphoma. ASH 2024;Abstract 886.
Woyach J et al. Pirtobrutinib vs ibrutinib in treatment-naïve and relapsed/refractory CLL/SLL: Results from the first randomized phase III study comparing a non-covalent and covalent BTK inhibitor. ASH 2025;Abstract 683.
Woyach JA et al. First-in-human study of the reversible BTK inhibitor nemtabrutinib in patients with relapsed/refractory chronic lymphocytic leukemia and B-cell non-hodgkin lymphoma. Cancer Discov 2024;14(1):66-75. Abstract
Dr Fakhri
Ahn I et al. Updated efficacy and safety results of the Bruton tyrosine kinase (BTK) degrader BGB- 16673 in patients with relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) from the ongoing phase 1 CaDAnCe-101 study. ASH 2025;Abstract 85.
Omer Z et al. Bexobrutideg (NX-958), a novel Bruton’s tyrosine kinase (BTK) degrader, demonstrates rapid and durable clinical responses in relapsed/refractory chronic lymphocytic leukemia (CLL): New and updated findings from an ongoing Phase 1a/b trial. ASH 2025;Abstract 86.
Winter AM et al. Real-world outcomes of lisocabtagene maraleucel (liso-cel) in patients (pt) with Richter transformation (RT) from the Center for International Blood and Marrow Transplant Research (CIBMTR). ASCO 2024;Abstract 7010.
Woyach J et al. Updates of R/R CLL with prior exposure to Bruton’s tyrosine kinase (BTK) inhibitor and/or bcl-2 inhibitor in the phase 1 trial of LP-168 (rocbrutinib), a novel COVALENT and non-COVALENT BTK inhibitor. ASH 2025;Abstract 87.
Zhou K et al. Results of a registrational phase 2 study of lisaftoclax monotherapy for treatment of patients (pts) with relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) who had failed Bruton’s tyrosine kinase inhibitors (BTKis). ASH 2025;Abstract 88.